Clinical Trial Update: T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CRISPR PD-1-edited tumor-infiltrating lymphocytes for metastatic melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CRISPR PD-1-edited tumor-infiltrating lymphocytes

Snippet

Sponsor: Inge Marie Svane | Conditions: Melanoma Metastatic | Phase 1 | Status: RECRUITING